Canny Clozel Gets Another $230m From J&J For Idorsia Hypertension Drug
Executive Summary
Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.
You may also be interested in...
Idorsia And J&J Hypertension Drug Edges Closer To An Uncertain Market
The partners released positive data from a Phase III study of their resistant hypertension drug candidate, aprocitentan, and have already started talks with regulators, but its commercial prospects remain uncertain.
Idorsia Raises $630m For Daridorexant Launch And Pipeline Push
With the US filing of its non-sedative sleeping pill now imminent, the Swiss biotech is also adding to its war chest to advance Phase III drugs aprocitentan, clazosentan and lucerastat.
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.